- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02979613
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Chiayi City, 대만, 60002
-
Kaohsiung, 대만
-
Taipei City, 대만, 10002
-
-
-
-
-
Daegu, 대한민국, 700-721
-
Seoul, 대한민국
-
Seoul, 대한민국, 135-710
-
Seoul, 대한민국, 05505
-
Seoul, 대한민국, 03722
-
Seoul, 대한민국, 152-703
-
Seoul, 대한민국, 06973
-
Seoul, 대한민국, 03830
-
-
Gyeonggi-d
-
Goyang, Gyeonggi-d, 대한민국
-
-
-
-
California
-
Los Angeles, California, 미국
-
Palo Alto, California, 미국
-
Pasadena, California, 미국
-
San Diego, California, 미국
-
San Francisco, California, 미국
-
San Jose, California, 미국
-
-
Maryland
-
Baltimore, Maryland, 미국
-
-
Massachusetts
-
Boston, Massachusetts, 미국
-
-
Michigan
-
Novi, Michigan, 미국
-
-
New York
-
Flushing, New York, 미국
-
Flushing, New York, 미국, 11355
-
New York, New York, 미국
-
New York, New York, 미국, 10029
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국
-
Philadelphia, Pennsylvania, 미국, 19107
-
-
Tennessee
-
Nashville, Tennessee, 미국
-
-
Texas
-
Sugar Land, Texas, 미국, 77478
-
-
-
-
-
Barcelona, 스페인
-
Majadahonda, 스페인
-
-
-
-
-
London, 영국
-
London, 영국, E1 1BB
-
-
-
-
-
Milan, 이탈리아, 20122
-
-
-
-
-
Edmonton, 캐나다
-
Toronto, 캐나다
-
Vancouver, 캐나다
-
-
-
-
-
Hong Kong, 홍콩
-
Kowloon, 홍콩
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures
- Adult male and non-pregnant, non-lactating females
- Documented evidence of chronic hepatitis B virus (HBV) infection previously
- Maintained on tenofovir disoproxil fumarate (TDF) 300 mg once daily for at least 48 weeks, and as monotherapy for chronic hepatitis B for at least 24 weeks with viral suppression (HBV DNA < lower limit of quantitation) for a minimum of 12 weeks prior to screening
- Adequate renal function
- Normal Electrocardiogram
Key Exclusion Criteria:
- Pregnant women or women who are breastfeeding
- Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
- Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus (HIV)
- Evidence of hepatocellular carcinoma
- Current evidence of, or recent (≤ 5 year) history of clinical hepatic decompensation
Abnormal hematological and biochemical parameters, including:
- Hemoglobin < 10 g/dL
- Absolute neutrophil count < 750/mm^3
- Platelets ≤ 50,000/mm^3
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 × upper limit of the normal (ULN)
- Albumin < 3.0 mg/ dL
- International normalized ratio (INR) > 1.5 × ULN (unless stable on anticoagulant regimen)
- Total bilirubin > 2.5 × ULN
- Received solid organ or bone marrow transplant
- Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (eg, basal cell skin cancer). Individuals under evaluation for possible malignancy are not eligible.
- Currently receiving therapy with immunomodulators (eg, corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion
- Individuals receiving ongoing therapy with drugs not to be used with TAF or TDF or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
- Current alcohol or substance abuse judged by the investigator to potentially interfere with compliance
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements.
- Use of investigational agents within 3 months of screening, unless allowed by the sponsor
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: TAF 25 mg
Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks.
Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
|
25mg 정제를 1일 1회 경구 투여
다른 이름들:
1일 1회 경구 투여되는 정제
|
활성 비교기: TDF 300 mg
DB phase: TDF 300 mg + TAF placebo for up to 50 weeks.
OLE phase: TAF 25 mg for up to 52 weeks.
|
25mg 정제를 1일 1회 경구 투여
다른 이름들:
300 mg 정제를 1일 1회 경구 투여
다른 이름들:
1일 1회 경구 투여되는 정제
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
기간: Week 48
|
The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:
|
Week 48
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants With HBV DNA Levels ≥ 20 IU/mL at Week 96, as Determined by the Modified US FDA-Defined Snapshot Algorithm
기간: Week 96
|
The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:
|
Week 96
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 48
기간: Weeks 48
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window.
Missing=Failure (M = F) approach was used for analysis.
|
Weeks 48
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 48
기간: Week 48
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window.
The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches.
|
Week 48
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 96
기간: Week 96
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window.
M = F approach was used for analysis.
|
Week 96
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 96
기간: Week 96
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window.
The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches.
|
Week 96
|
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 48
기간: Week 48
|
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBeAg Seroconversion at Week 48
기간: Week 48
|
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBeAg Loss at Week 96
기간: Week 96
|
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With HBeAg Seroconversion at Week 96
기간: Week 96
|
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
기간: Week 48
|
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBsAg Seroconversion at Week 48
기간: Week 48
|
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBsAg Loss at Week 96
기간: Week 96
|
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With HBsAg Seroconversion at Week 96
기간: Week 96
|
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48 (by Central Laboratory and the American Association for the Study of Liver Diseases [AASLD] Criteria)
기간: Week 48
|
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 48
|
Percentage of Participants With Normalized ALT at Week 48 (by Central Laboratory and AASLD Criteria)
기간: Week 48
|
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 48
|
Percentage of Participants With Normal ALT at Week 96 (by Central Laboratory and the AASLD Criteria)
기간: Week 96
|
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 96
|
Percentage of Participants With Normalized ALT at Week 96 (by Central Laboratory and AASLD Criteria)
기간: Week 96
|
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 96
|
Change From Baseline in FibroTest® Score at Week 48
기간: Baseline; Week 48
|
The FibroTest score is used to assess liver fibrosis.
Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
|
Baseline; Week 48
|
Change From Baseline in FibroTest® Score at Week 96
기간: Baseline; Week 96
|
The FibroTest score is used to assess liver fibrosis.
Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
|
Baseline; Week 96
|
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
기간: Baseline; Week 48
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 48
|
Percent Change From Baseline in Hip BMD at Week 96
기간: Baseline; Week 96
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 96
|
Percent Change From Baseline in Spine BMD at Week 48
기간: Baseline; Week 48
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 48
|
Percent Change From Baseline in Spine BMD at Week 96
기간: Baseline; Week 96
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 96
|
Change From Baseline in Estimated Glomerular Filtration Rate Calculated Using the Cockcroft-Gault Equation (eGFR-CG) at Week 48
기간: Baseline; Week 48
|
Cockcroft-Gault formula is as follows:
Change from baseline was calculated as the value at Week 48 minus the value at Baseline. |
Baseline; Week 48
|
Change From Baseline in eGFR-CG at Week 96
기간: Baseline; Week 96
|
Cockcroft-Gault formula is as follows:
Change from baseline was calculated as the value at Week 96 minus the value at Baseline. |
Baseline; Week 96
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GS-US-320-4018
- 2016-003632-20 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 B형 간염에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Pfizer완전한수막구균 B 질병호주, 폴란드, 핀란드, 체코
-
Canadian Immunization Research NetworkUniversity of British Columbia; University of Calgary; Dalhousie University; Université de...완전한
-
Jiangsu HengRui Medicine Co., Ltd.모집하지 않고 적극적으로
-
Hebei Senlang Biotechnology Inc., Ltd.Tongji Hospital모병
-
Masonic Cancer Center, University of Minnesota완전한난치성 B-혈통 백혈병 | 재발된 B 계통 백혈병 | 난치성 B 계통 림프종 | 재발된 B 계통 림프종미국
-
Fundamenta Therapeutics, Ltd.The First Affiliated Hospital of USTC (Anhui Provincial Hospital)모병
TAF에 대한 임상 시험
-
Gilead Sciences완전한
-
Gilead Sciences아직 모집하지 않음
-
Huashan HospitalThe First Affiliated Hospital with Nanjing Medical University; Peking University First... 그리고 다른 협력자들모병
-
Gilead Sciences모병
-
Gilead Sciences완전한
-
Gilead Sciences완전한
-
Janssen Scientific Affairs, LLC완전한